Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chabiotech | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩583.25B | -65.2x | -19.4 | ₩10,230 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GC Cell | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩301.29B | -4.3x | 0 | ₩20,050 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Labgenomics | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩159.99B | -6.4x | 0.02 | ₩2,105 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dreamcis | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩70.21B | 12.8x | 0.32 | ₩2,980 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
DT CRO | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩53.85B | ₩4,200 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Biotoxtech | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩46.06B | -6.5x | 0.23 | ₩2,880 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
U2Bio | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩36.91B | ₩3,250 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
SLS Bio | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩22.22B | ₩2,115 | 30% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |